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Abstract
Background: Epicardial adipose tissue (EAT) is a newly discovered independent risk factor for coronary
atherosclerosis. There is a scarcity of information on the reduction of EAT volume to reduce atherosclerosis risk.
Coronary computed tomography angiography (CCTA) has emerged as a noninvasive imaging method for the
analysis of coronary atherosclerosis and EAT volume. The purpose of this trial is to determine whether olmesartan
medoxomil is effective at both treatment of coronary atherosclerosis progression and EAT volume reduction in
patients with coronary atherosclerosis detected by CCTA.
Methods/design: This study is a prospective, single-center, open-label, randomized controlled clinical trial aimed
at exploring the efficacy of olmesartan medoxomil on coronary atherosclerosis and EAT. A total of 194 patients
with coronary stenosis greater than 30 % and less than 70 % detected by CCTA will be randomly divided into
olmesartan medoxomil or conventional antihypertensive medication groups (1:1 ratio). The primary outcome
measures include coronary atherosclerosis progression and EAT volume reduction, as detected by CCTA at
12 months. The secondary outcome measures include the levels of blood lipids, glucose, high-sensitivity C-reactive
protein, IL-6, monocyte chemotactic protein 1, TNF-α, matrix metalloproteinase 9, NO, endothelin 1, adiponectin,
and leptin at baseline and after 6 and 12 months.
Discussion: Treatments aimed at reducing EAT volume can eventually achieve an antiatherosclerotic effect. This is
the first trial designed to explore the effect of olmesartan medoxomil on both coronary atherosclerosis progression
and EAT volume reduction in patients with coronary atherosclerosis detected by CCTA.
Trial registration: ClinicalTrials.gov: NCT02360956.
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Background
Epicardial adipose tissue and coronary atherosclerosis
Epicardial adipose tissue (EAT) is directly deposited
around the pericardium and coronary artery. By auto-
crine and paracrine means, EAT can generate various
kinds of cytokines, inflammatory mediators and free fatty
acids. These biological indicators can affect the state of
coronary endothelial function and promote inflammation
and oxidative stress, which finally aggravate the progres-
sion of coronary atherosclerosis [1–3]. A significant
amount of clinical research has been conducted to investi-
gate the link between EAT and coronary atherosclerosis. It
was claimed that calcified plaque progression in patients
without coronary artery disease and in patients with type
2 diabetes mellitus were associated with a larger EAT vol-
ume [4, 5]. Epicardial adipose tissue is also an independent
predictor of significant coronary stenosis and is independ-
ently associated with high-risk coronary plaque features,
such as low CT attenuation plaque, thin-cap fibroather-
oma and positive remodeling [6]. Not only is EAT, as a
special visceral fat, correlated with the increased deve-
lopment of coronary artery atherosclerosis, but it is also
associated with adverse coronary events [7].
Treatment of epicardial adipose tissue and coronary
atherosclerosis
There are ample studies exploring the progression of
coronary atherosclerosis following pharmacological ma-
nipulation. At the time of writing, the use of statins is
recognized as an effective treatment; statins can result in
decreases in plaque and necrotic core volume, and can
also significantly reduce the progression of low attenu-
ation plaque (<30 Hounsfield units) and non-calcified
plaque [8, 9]. Other drugs, such as dipeptidyl-peptidase
4 inhibitors [10], a PPARγ agonist (pioglitazone) [11],
atorvastatin plus ezetimibe [12], olmesartan [13], have
also been reported to have antiatherosclerotic effects, al-
though the effects have not been verified by large-scale
studies. As studies show that EAT volume is associated
with plaque progression and cardiovascular adverse
events, treatments aimed at reducing EAT volume may
finally achieve an antiatherosclerotic, preventive effect.
However, at the time of writing, limited studies have
aimed at reducing both EAT and plaque volume to
achieve an antiatherosclerotic effect. A serial coronary
computed tomography angiography (CCTA) study re-
cently indicated that intensive statin therapy can reduce
the EAT volume of Europeans, but the study failed to
demonstrate a relationship among EAT volume reduc-
tion, coronary atherosclerosis progression and clinical
prognosis [14]; moreover, intensive statin therapy might
not be appropriate for Asians. The epidemiological studies
and clinical researches show that Asians may have poorer
tolerability and safety to intensive statins than white
people, owing to genetic differences (variants in structure
or polymorphisms) in pharmacokinetics and pharma-
codynamics properties [15–17]. It has been claimed that
polymorphic variants in cytochrome P450 (CYP450) fam-
ilies that were associated with statin metabolism might re-
sult in varying rates of metabolic clearance. CYP450 2C19
slow metabolizer phenotype was reported to be present in
approximately 16 % of Asians compared with only about
3 % of white people [18]. Polymorphic variants in the pre-
dominant CYP450 isoform, CYP450 3A4, were reported
to be associated with a functional decrease in the enzyme’s
activity in dyslipidemic Chinese patients [19]. The HPS2-
THRIVE study recently also indicated that, using same-
dose statin treatment, an excess of increased alanine ami-
notransferase was seen mainly among Chinese patients
(more than three consecutive values above the upper limit
of normal of 0.24 %/year compared with 0.02 %/year in
Europe) [20]. Moreover, the morbidity of chronic hepatitis
B was high in china with nearly 90 million infections. For
these reasons, intensive statin therapy may result in higher
hepatotoxicity in Asian populations than in white popula-
tions, so low- to moderate- dose statin therapy might be
more appropriate for Asian populations [15, 16]. Subjects
who undergo weight loss exercise, bariatric surgery, or
low-dose aspirin therapy can also reduce EAT volume or
inflammation, but the effects are weak and these treat-
ments cannot achieve good results in patients with coron-
ary atherosclerosis progression [21–24]. Our aim is to find
a drug that reduces EAT volume while inhibiting the pro-
gression of coronary atherosclerosis.
In recent years, studies have confirmed that olmesar-
tan medoxomil can improve endothelial function, resist
thrombosis, improve tissue reconstruction, and resist
oxidative stress to achieve atherosclerosis resistance
[13, 25–28]. The latest research shows that olmesartan
medoxomil can better inhibit rat epididymal adipose cell
hypertrophy and inflammatory reactions [29]. Therefore,
we hypothesized that olmesartan medoxomil may also re-
duce EAT volume, finally achieving an anti-atherosclerosis
effect.
EAT and coronary atherosclerosis imaging with computed
tomography
Compared with such invasive methods as intravascular
ultrasound, virtual histology intravascular ultrasound,
optical coherence tomography, and fractional flow reserve,
CCTA has emerged as a noninvasive imaging method that
analyzes both coronary atherosclerosis and EAT volume
[14, 30]. To date, ample CCTA studies have explored the
progression of coronary atherosclerosis following pharma-
cological manipulation. Thus, in this study, using CCTA
as a noninvasive method to analyze both coronary athero-
sclerosis progression and EAT volume is of significant
clinical value.
Zhou et al. Trials  (2016) 17:10 Page 2 of 8
Aims of the main study
The purpose of this study is to determine whether olme-
sartan medoxomil is effective on both the treatment of
coronary atherosclerosis progression and EAT volume re-
duction in patients with coronary atherosclerosis detected
by CCTA.
Aims of the anti-atherosclerosis mechanism study
1. To explore the relationship between coronary
atherosclerosis progression and EAT volume
reduction.
2. To explore the effect of olmesartan medoxomil on
serum levels of blood lipids, glucose, circulating
surrogate markers of atherosclerosis inflammation,
including high-sensitivity C-reactive protein, IL-6,
monocyte chemotactic protein 1 (MCP-1), TNF-α,
and matrix metalloproteinase 9 (MMP-9), circulating
surrogate markers of endothelial function, including
NO and endothelin 1 (ET-1), and circulating
surrogate markers of adipose tissue inflammation
and metabolism, including adiponectin and leptin
at baseline and after 6 and 12 months.
Methods/design
Study design
This study is a prospective, single-center (Chinese PLA
General Hospital, Beijing, China), open-label, randomized
controlled trial of the efficacy of olmesartan medoxomil
on coronary atherosclerosis and EAT. Consecutive pa-
tients with coronary stenosis greater than 30 % and less
than 70 % detected by CCTA will be randomly assigned to
olmesartan medoxomil or conventional antihypertensive
medication groups (1:1 ratio). Coronary computed tomog-
raphy angiography will be conducted at the Department
of Cardiology (Chinese PLA General Hospital). Primary
outcome measures include coronary atherosclerosis pro-
gression and EAT volume reduction, as detected by
CCTA, at 12 months. Secondary outcome measures in-
clude levels of blood lipids, glucose, high-sensitivity C-
reactive protein, IL-6, MCP-1, TNF-α, MMP-9, NO, ET-1,
adiponectin, and leptin at baseline and after 6 and
12 months. The study design is summarized in Fig. 1.
Clinical inclusion and exclusion criteria
Clinical inclusion criteria are:
 Age between 18 and 75 years;
 Coronary artery stenosis between 30 % and 70 %
determined by CCTA in essential hypertension
patients;
 Resting diastolic blood pressure between 90 and
110 mmHg;
 Type A and B for coronary artery vascular lesions.
Clinical exclusion criteria are:
 Secondary hypertension;
 Coronary artery stenosis less than 30 % or greater
than 70 %, as determined by CCTA;
 Severe arrhythmia;
 Severe cardiac insufficiency or left ventricular
dysfunction (left ventricular ejection
fraction < 30 %);
 Severe hepatic or kidney insufficiency;
 Resting systolic blood pressure > 200 mmHg or
resting diastolic blood pressure >110 mmHg;
 Contraindications to treatment with olmesartan
medoxomil (allergy, glaucoma, digestive ulcer,
currently taking phosphodiesterase-5 inhibitor);
 Severe calcification, distortion or type C coronary
artery vascular lesions;
 Pregnancy;
 Unwillingness or inability to provide informed
consent.
Randomization
Information regarding the study will be provided to the
patient at the Department of Cardiology. Once informed
consent is obtained, the patient will be randomized at
the Department of Cardiology. Subjects will be random-
ized to either olmesartan medoxomil or conventional
antihypertensive medication groups (1:1 ratio). Partici-
pants will be randomized before the first treatment using
a blocked randomization procedure (computerized random
numbers) and will incorporate minimization to ensure
matching for age, sex, body mass index, and hypertension
grade.
Ethical considerations
The Chinese PLA General Hospital Ethics Committee
approved this study on 12 December 2014 (reference
number S2014-119-01). This study complies with the
Declaration of Helsinki. Informed consent will be obtained
from all participating patients. Upon signing informed
consent, patients’ data will be populated as per protocol.
Details of CCTA examination
CCTA examination procedure
CCTA will be performed on a dual-source CT scan-
ner (Somatom Definition Flash, Siemens Healthcare,
Forchheim, Germany). All enrolled patients will be ins-
tructed in the breath-holding technique before CCTA to
minimize breathing artifacts. Three minutes before CCTA,
all patients will be given 0.5 mg nitroglycerin sublingually
to dilate the coronary artery. The scan range is from the
carina or the pulmonary artery segment down to 1 cm
below the diaphragm. Electrocardiography is continuously
performed throughout the entire examination for each
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patient. A dual-head power injector (SCT 210, Medrad,
USA) and a nonionic contrast medium (Ultravist®, 370 mg
I /ml, Schering AG, Guangzhou, China) will be used. The
collimation is 2 × 128 × 0.6 mm, the gantry rotation time
is 0.28 ms, the slice thickness is 0.6 mm, the tube voltage
is 80 to 120 kV (modified using a care kV, Siemens Med-
ical Solutions, Forchheim, Germany), and the tube current
is 290 to 560 mAs/rotation (scout-based automatic refer-
ence tube current selection – CareDose 4D, Siemens
Medical Solutions, Forchheim, Germany). For double flash
acquisition, the pitch is 3.4, and for retrospectively ECG-
triggered spiral acquisition, the pitch will vary depending
on the patient’s heart rate. Total estimated radiation dose
for the patient will be recorded.
Patients with a heart rate ≤70 beats/min will be evalu-
ated using double prospective ECG-gated high-pitch CT
angiography (double flash mode). For the double flash
protocol, the contrast-enhanced CCTA protocol is as
follows: a test bolus scan will be performed at the level
of the aortic root with administration of 15 ml of
contrast medium into the right antecubital vein at a rate
of 5.0 ml/s, followed by an injection of 20 ml of saline
flush at the same flow rate to obtain a peak enhance-
ment time curve. The double flash acquisition triggered
scan time is 4 s after the peak enhancement time. After
calculating the triggered scan time, double flash acquisi-
tion will be performed by injecting 60 to 90 ml contrast
medium at a rate of 5.0 ml/s, immediately followed by
35 ml of 70/30 contrast/saline material mixture and
50 ml saline bolus at the same flow rate. The first scan
will begin at 60 % of the R-R interval from the cranio-
caudal direction. The second scan will be acquired at
30 % of the R-R interval 3 s after the first scan during
the same contrast injection time.
Patients with a heart rate >70 beats/min will be evalu-
ated using retrospectively ECG-triggered spiral acquisi-
tion. The retrospective protocol is as follows: 60 to
90 ml contrast medium is injected into the antecubital
vein at a rate of 5.0 ml/s, immediately followed by 50 ml
saline solution at the same flow rate. Bolus tracking is
Fig. 1 Study flowchart. CCTA, coronary computed tomography angiography; DBP, diastolic blood pressure; EAT, epicardial adipose tissue; SBP,
systolic blood pressure
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used, and the region of interest is set at the root of the
ascending aorta. We will perform the scan with a delay
of 5 s after the root of the ascending aorta reaches a
threshold of 100 Hounsfield units. For this scan mode,
the acquisition is from 30 % to 80 % of the R-R interval.
CCTA image post-processing
All CCTA data will be sent to the Syngo Multi-Modality
Workplace for post-processing. Two independent expe-
rienced observers who are unaware of the patients’ clin-
ical information will evaluate the CCTA data in different
modes, including maximum intensity projection, volume
rendering, curved-planar reconstructions, and the ori-
ginal transaxial images. Disagreements in data analysis
between the two readers will be resolved by consensus
reading.
Epicardial adipose tissue quantification
The EAT volume will be measured by two experienced
radiologists using the same sets of images acquired for
the CCTA. The radiologists will be blinded to the pur-
pose of the study, clinical characteristics and patients’
anthropometric data.
The EAT volume is defined as the total amount of adi-
pose tissue deposited between the surface of the heart
and the visceral pericardium. The region of interest in
measuring the EAT volume includes the heart and the
surrounding EAT. By manually tracing the epicardium
contours in the axial slices from the bifurcation of the
pulmonary artery to the diaphragm, the EAT volume is
analyzed. The pericardium contour is traced every
10 mm, from the lower visible level of the pulmonary ar-
tery bifurcation until the top level of the pulmonary
valve, for every 20 mm until the first slice where the dia-
phragm becomes visible, and for every 10 mm from this
point until the last slice where the pericardium is still
visible [31]. The pericardium contour is manually out-
lined by the radiologists, and then the software (Syngo
Volume, Siemens Medical Solutions) automatically calcu-
lates the total EAT volume. Computed tomography at-
tenuation ranging from −195 to 45 Hounsfield units
is applied to isolate the EAT from other tissues. Me-
diastinal adipose tissue and pericardial adipose fat (fat
deposit outside the visceral pericardium and on the
external surface of the parietal pericardium) are excluded
from the analysis. For the assessment of interobserver
agreement, we will randomly select 50 patients, and
all EAT measures will be assessed by two experi-
enced radiologists blinded to the other radiologist’s
measurements.
Definition of coronary atherosclerosis plaque progression
We will use QAngio CT post-processing software (QAn-
gioCT Research Edition version 2.1.0, Medis Medical
Imaging Systems, Leiden, the Netherlands) to evaluate
all CCTA data. All three vessels will be assessed in each
patient using the 15-segment American Heart Association
model for coronary segment classification [32]. Only seg-
ments with a diameter ≥2.0 mm and without stent im-
plantation will be considered for analysis. Parameters
including minimal lumen diameter, percent diameter sten-
osis, minimum lumen area, plaque burden, plaque vol-
ume, vascular remodeling index, plaque type classification
(calcification, necrosis, fiber, and fiber lipid plaques) based
on segments will be analyzed using QAngio CT post-
processing software.
Coronary atherosclerosis progression is defined as ≥10 %
diameter reduction or progression of a pre-existing coron-
ary stenosis or ≥0.2 mm reduction or progression of the
minimal luminal diameter in the lesion [30].
Medication intervention and control protocols
All patients should accept lifestyle interventions and con-
ventional anti-atherosclerosis treatment. The low-density
lipoprotein cholesterol level should be controlled below
100 mg/dl, and the blood pressure should be controlled
below 140/90 mmHg.
In the olmesartan medoxomil group, the usual rec-
ommended starting dose of olmesartan medoxomil is
20 mg once daily when used as monotherapy in pa-
tients who are not volume-contracted. For patients
requiring further reduction in blood pressure after
2 weeks of therapy, the dose of olmesartan medoxo-
mil may be increased to 40 mg. Doses above 40 mg
do not appear to have a greater effect. Twice-daily
dosing offers no advantage over the same total dose given
once daily.
In the control group, any antihypertensive medication
alone or in combination, including calcium channel
blockers, diuretics, beta blockers, or other antihyperten-
sive medication except angiotensin-converting enzyme in-
hibitors or angiotensin II receptor blockers can be used.
The drug dose must be individualized. The patients
should take the antihypertensive drugs according to the
doctors’ recommendations.
Study outcomes
The primary outcome measures are coronary atheroscler-
osis progression and EAT volume changes, as detected by
CCTA at 12 months.
The secondary outcome measures include
1. The relationship between coronary atherosclerosis
and EAT;
2. Serum levels of blood lipids, glucose, circulating
surrogate markers of atherosclerotic inflammation
including high-sensitivity C-reactive protein, IL-6,
MCP-1, TNF-α, and MMP-9, individual circulating
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surrogate markers of endothelial function including
NO and ET-1, and individual circulating surrogate
markers of adipose tissue inflammation and
metabolism including adiponectin and leptin at
baseline and after 6 and 12 months.
Biomarkers
Two 10-ml samples of blood will be collected from
the antecubital vein by a trained nurse for each indi-
vidual. Fasting blood samples will be obtained between
7:00 a.m. and 12:00 noon to control for possible diurnal
variations. Blood samples will be centrifuged at 4 °C and
3,000 rpm for 15 min. The serum will be sampled and
stored at −80 °C until analysis. Traditional cardiovascular
blood risk markers, including fasting blood glucose, tri-
glycerides, total cholesterol, and high- and low-density
lipoprotein cholesterol will be assessed. The following
proinflammatory markers will be assessed: high-sensitivity
C-reactive protein, IL-6, TNF-α, MCP-1, and MMP-9. In
addition, NO and ET-1 will be measured, to assess endo-
thelial function. Markers of adipose tissue inflammation
and metabolism, including adiponectin and leptin, will
also be assessed. These markers will be measured at base-
line and 6 and 12 months after treatment.
Follow-up
Clinical follow-up will take place at 1 month (±1 week),
3 months (±2 weeks), 6 months (±2 weeks), 9 months
(±30 days), and 1 year (±30 days) by clinical visit or phone
interview.
At baseline and 6-month (±2 weeks) and 1 year
(±30 days) follow-ups, all patients will provide venous
blood for detection of blood lipids, glucose, high-sensitivity
C-reactive protein, IL-6, MCP-1, TNF-α, NO, ET-1, MMP-
9, adiponectin, and leptin.
At 1 year (±30 days) follow-up, all patients will undergo
CCTA (with QAngio CT post-processing software).We
anticipated a patient drop-out rate of 10 %.
Sample size calculation
This trial is an open-label randomized clinical trial,
so patients will randomly be assigned to olmesartan
medoxomil or conventional antihypertensive medication
groups (1:1 ratio). The purpose of this study is to verify
that olmesartan medoxomil is effective in the treatment of
coronary atherosclerosis progression and EAT volume re-
duction in patients with coronary atherosclerosis detected
by CCTA. We also want to elucidate the relationship be-
tween coronary atherosclerosis and EAT. The mechanism
by which olmesartan medoxomil inhibits coronary athero-
sclerosis progression will be studied by detecting the
serum levels of blood lipids, glucose, circulating surrogate
markers of atherosclerosis inflammation including high-
sensitivity C-reactive protein, IL-6, MCP-1, TNF-α, and
MMP-9, circulating surrogate markers of endothelial
function, including NO and ET-1, and circulating surro-
gate markers of adipose tissue inflammation and metabol-
ism, including adiponectin and leptin.
Studies on coronary atherosclerosis progression rate
have had differing results. The combined results of mul-
tiple studies indicate that the conventional mean coronary
atherosclerosis progression rate is about 30 % [33–35].
We hypothesize that additional olmesartan medoxomil
use will reduce the coronary atherosclerosis progres-
sion rate to 13 % [36–40]. Using double-side inspection,
α = 0.05, β = 0.2, we calculate a total sample size of 176
cases; considering the expected loss to follow-up to be
10 %, the number of cases to be included should be at
least 176 × (1 + 10 %) = 194. Therefore, we aim for 97
cases of each group.
Statistical analysis
Continuous variables will be described using means and
standard deviations or median and range in case of asym-
metric distribution of data. Categorical variables will be pre-
sented using frequency distribution. Univariate analyses will
be conducted using chi-square and t tests for independent
samples. A multiple logistic regression analysis will be per-
formed to correlate coronary atherosclerosis progression
with clinical variables and EAT volume, including treatment
groups. Statistical significance will be considered for P <
0.05. A statistical package (SPSS 16.0) will be used for ana-
lysis. The individual will be considered the unit of analysis.
Discussion
To date, there are ample CCTA studies exploring the pro-
gression of coronary atherosclerosis following pharmaco-
logical manipulation. As studies show that EAT volume is
associated with plaque progression and cardiovascular
adverse events, treatments aimed at reducing EAT volume
may finally achieve an antiatherosclerotic, preventive ef-
fect. However, at the time of writing, only a limited num-
ber of studies have aimed to reduce both EAT and plaque
volume to achieve a preventive effect against atheroscler-
osis. The novelty of this study is that we intend to explore
the effect of olmesartan medoxomil on both plaque vol-
ume and epicardial fat. This study will accomplish two
goals: (1) it will explain the relationship between EAT
volume and coronary atherosclerosis progression and (2)
it will verify the effect of olmesartan medoxomil on EAT
volume reduction and coronary atherosclerosis progression.
If these hypotheses are supported, the study findings
will have significant implications related to clinical prac-
tice. Evidence that olmesartan medoxomil is effective on
EAT volume reduction and coronary atherosclerosis
progression would be very attractive to clinicians and
patients. This may further contribute to the care of pa-
tients with coronary heart disease.
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Trial status
Recruitment for the study is currently ongoing. Patient
recruitment began in December 2014.
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